Your browser is no longer supported. Please, upgrade your browser.
ABBV AbbVie Inc. daily Stock Chart
AbbVie Inc.
IndexS&P 500 P/E16.84 EPS (ttm)3.14 Insider Own0.10% Shs Outstand1.63B Perf Week-2.76%
Market Cap86.46B Forward P/E8.90 EPS next Y5.95 Insider Trans0.00% Shs Float1.61B Perf Month-6.58%
Income5.14B PEG0.87 EPS next Q1.14 Inst Own73.40% Short Float1.52% Perf Quarter-14.86%
Sales22.86B P/S3.78 EPS this Y185.50% Inst Trans1.90% Short Ratio2.75 Perf Half Y-21.39%
Book/sh2.97 P/B17.81 EPS next Y18.17% ROA12.60% Target Price72.81 Perf Year-3.71%
Cash/sh5.66 P/C9.35 EPS next 5Y19.39% ROE152.60% 52W Range44.98 - 70.21 Perf YTD-9.78%
Dividend2.28 P/FCF- EPS past 5Y3.50% ROI36.10% 52W High-24.67% Beta-
Dividend %4.31% Quick Ratio1.80 Sales past 5Y7.90% Gross Margin80.70% 52W Low17.59% ATR2.47
Employees26000 Current Ratio2.00 Sales Q/Q17.40% Oper. Margin33.00% RSI (14)41.03 Volatility4.66% 5.15%
OptionableYes Debt/Eq6.61 EPS Q/Q282.40% Profit Margin22.50% Rel Volume1.05 Prev Close53.12
ShortableYes LT Debt/Eq6.45 EarningsJan 29 BMO Payout64.60% Avg Volume8.88M Price52.89
Recom2.10 SMA20-5.12% SMA50-6.37% SMA200-13.17% Volume9,274,000 Change-0.43%
Dec-01-15Downgrade Barclays Overweight → Equal Weight $73 → $72
Nov-02-15Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-23-15Reiterated UBS Buy $81 → $78
Sep-28-15Upgrade Citigroup Sell → Neutral
Jul-22-15Initiated Sun Trust Rbsn Humphrey Buy
Jun-17-15Initiated Piper Jaffray Overweight
Jun-08-15Reiterated Jefferies Buy $86 → $90
May-28-15Resumed Morgan Stanley Equal-Weight $72
May-27-15Resumed JP Morgan Overweight $75
Jan-06-15Reiterated UBS Buy $72 → $76
Nov-26-14Reiterated Argus Buy $65 → $85
Nov-14-14Initiated Deutsche Bank Buy $80
Jul-28-14Upgrade UBS Neutral → Buy $57 → $67
Jun-24-14Reiterated Argus Buy $59 → $65
Jan-06-14Reiterated UBS Neutral $46 → $56
Oct-29-13Reiterated Argus Buy $52 → $59
Aug-12-13Initiated Argus Buy $52
May-15-13Reiterated R. F. Lafferty Buy $47.90 → $61
Apr-29-13Reiterated Barclays Equal Weight $41 → $44
Apr-15-13Reiterated Barclays Equal Weight $37 → $41
Feb-09-16 07:31AM  20 dividend stocks that Wall Street loves the most at MarketWatch
Feb-08-16 10:44AM  The market in a minute: 5 stocks I really like at MarketWatch
08:25AM  4 Big Dividend Pharmaceutical Stocks to Buy That Are Very Cheap Now at 24/7 Wall St.
Feb-07-16 07:11AM  Is Gilead Sciences Finally Nearing a Bottom? at Motley Fool
Feb-06-16 07:06AM  Eli Lilly and Co.s 4Q15 Business Segment Performance
07:06AM  Why Halozyme Therapeutics Inc Plunged 51% in January at Motley Fool
Feb-05-16 10:17PM  [$$] J&J, AbbVie Shares Drop on Potential Drug Competition at The Wall Street Journal -6.41%
03:40PM  Gilead Sciences 2016 Guidance: Sandbagging Wall Street Again? at Motley Fool
01:22PM  [$$] J&J, AbbVie Shares Drop on Potential Drug Competition at The Wall Street Journal
Feb-04-16 02:29PM  Its Time to Buy This Biotech Gem
09:30AM  The Zacks Analyst Blog Highlights: Biogen, Gilead, AbbVie, Intrexon and NewLink
08:35AM  Factors of Influence in Today's Market - Analyst Notes on General Motors, AbbVie, Yum! Brands and Philip Morris International Accesswire
Feb-03-16 10:02AM  The Real Risks of Gileads Stock +5.36%
09:00AM  Gilead (GILD) Beats Q4 Earnings Estimates, Gives 2016 View
08:28AM  Biotech Stock Roundup: Biogen, Amgen Top Estimates; Zika Virus Grabs Attention
12:00AM  Seven $1 billion-plus drugs seen reaching market in 2016 Reuters
Feb-02-16 06:35PM  Gilead Q4 Earnings Beat Estimates; Guidance In Line With Street
05:40PM  Why Regeneron Pharmaceuticals Shares Fell 23% in January at Motley Fool
10:02AM  AbbVie, Inc. Earnings Analysis: Q4, 2015 By the Numbers
07:57AM  Will Gilead Follow The Pfizer Game Plan For Sales Growth? at Forbes
Feb-01-16 10:31AM  Gilead Sciences: 'An Increasingly Tight Hep C Space Moving Forward,' Guggenheim Says at
Jan-31-16 02:00PM  [$$] Gilead risks becoming victim of its own success at Financial Times
07:40AM  Forget Biosimilars: It's This Threat That Could Dent AbbVie's Top Line at Motley Fool
Jan-30-16 03:34PM  AbbVie: There Ain't No Stinkin' Biosimilar Threat at Motley Fool
Jan-29-16 04:50PM  AbbVie Reports Mixed Q4 As Merck Launches Rival HCV Treatment
03:21PM  3 Health Care Stocks to Own in a Dangerous Market at TheStreet
02:04PM  Roche's (RHHBY) Earnings Miss Estimates, Revenues Beat
01:40PM  Payers see price leverage with entry of Merck hepatitis C drug Reuters
01:28PM  AbbVie Posts In-Line Earnings, Maintains 2016 Outlook
12:17PM  Gilead is Cheaper Than in 2008 and Six More Reasons to Buy at
11:54AM  Instant Analysis: Can Merck Make Waves In the Crowded Hepatitis C Space? at Motley Fool
11:43AM  [$$] Merck launches hepatitis C drug price war at Financial Times
11:42AM  Edited Transcript of ABBV earnings conference call or presentation 29-Jan-16 2:00pm GMT
11:28AM  With Merck Approval, Hepatitis-C Price War Back On at
10:58AM  FDA OKs Mercks new hepatitis C drug at MarketWatch
10:45AM  Investors Were Not Impressed With AbbVie Q4 Earnings
10:33AM  Merck's Hepatitis C Doublet Wins FDA Approval and Unveils Its Secret Weapon at Motley Fool
10:31AM  AbbVie cuts costs, turns profit that meets 4Q expectations
10:00AM  AbbVie quarterly revenue misses estimates, shares fall
09:24AM  AbbVie (ABBV) Stock Falling on Q4 Earnings Results at TheStreet
09:22AM  AbbVie's (ABBV) 4Q Earnings In-Line With Estimates
09:00AM  AbbVie Inc Earnings Call scheduled for 9:00 am ET today
08:26AM  [$$] AbbVie Results Top Expectations at The Wall Street Journal
08:21AM  AbbVie Reports Full-Year 2015 and Fourth-Quarter Financial Results at noodls
08:14AM  AbbVie Falling After Q4 Report, 2016 Guidance Affirmation
08:04AM  AbbVie beats fourth-quarter profit expectations at MarketWatch
07:55AM  ABBVIE INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
07:53AM  Drugmaker AbbVie reports higher quarterly revenue
07:49AM  AbbVie's Biggest Product Humira Narrowly Misses Estimates at Bloomberg
07:48AM  Bristol-Myers Squibb and AbbVie Receive Positive CHMP Opinion for Investigational Antibody, Empliciti (elotuzumab), for the Treatment of Multiple Myeloma in Patients Who Have Received at Least One Prior Therapy Business Wire
07:47AM  AbbVie Reports Full-Year 2015 and Fourth-Quarter Financial Results PR Newswire
07:07AM  Q4 2015 AbbVie Inc Earnings Release - Before Market Open
Jan-28-16 06:16PM  Merck Hepatitis C Drug to Enter Crowded Field With High Prices at Bloomberg
06:10PM  U.S. FDA approves Merck's new hepatitis C pill Reuters
02:34PM  What to Watch in the Day Ahead - Friday, Jan 29 Reuters
01:25PM  What to Look For in AbbVie Earnings
12:35PM  Like big pharma, biotech is toxic: Trader
12:27PM  AbbVie (ABBV) Stock Down Ahead of Q4 Earnings Results at TheStreet
08:40AM  Short Sellers Become More Selective on Major Pharma at 24/7 Wall St.
08:39AM  3 Things to Watch in Gilead Sciences' Q4 Results at Motley Fool
07:32AM  AbbVie Initiates Enrollment in Phase 3 Clinical Program for Elagolix in Patients with Uterine Fibroids at noodls
06:55AM  AbbVie Initiates Enrollment in Phase 3 Clinical Program for Elagolix in Patients with Uterine Fibroids PR Newswire
02:08AM  Venetoclax Receives 3rd Breakthrough Therapy Designation from the FDA for the Combination Treatment of Patients with Untreated Acute Myeloid Leukemia not Eligible for Standard Induction Chemotherapy at noodls
12:59AM  Venetoclax Receives 3rd Breakthrough Therapy Designation from the FDA for the Combination Treatment of Patients with Untreated Acute Myeloid Leukemia not Eligible for Standard Induction Chemotherapy PR Newswire
Jan-27-16 04:30PM  Will AbbVie (ABBV) Keep the Earnings Streak Alive in Q4?
04:20PM  Will Currency Volatility Keep Hurting Abbott's (ABT) Earnings?
Jan-26-16 01:30PM  Take Advantage Of The Correction: These Solid Dividend-Payers Are On Sale
07:26AM  AbbVies Net Profit Margin Expected to Reach 29.8% in 4Q15
07:26AM  AbbVie in 4Q15: Analysts Project Strong Revenue Growth
Jan-25-16 11:50AM  5 Big-Cap Drugmakers Reporting Q4 Earnings This Week; J&J First
09:14AM  Last-minute bulls charge into AbbVie
08:07AM  Otezlas Clinical Trials and Contribution to Celgene
08:00AM  Drug Manufacturers - Major Stocks on our Scanner -- Pfizer, AbbVie, Merck, and Johnson & Johnson Accesswire
Jan-24-16 11:14PM  [$$] Global pharma groups reveal tie-up with universities at Financial Times
11:43AM  What You Missed at the 2016 J.P. Morgan Healthcare Conference at Motley Fool
11:02AM  3 High-Yield Dividend Stocks Wealthy Investors Should Consider Buying at Motley Fool
Jan-23-16 12:01AM  [$$] Part 2 of the Barron's 2016 Roundtable: 31 Savvy Investment Ideas at
Jan-22-16 04:05PM  AbbVie Advanced Its Mid- and Late-Stage Research Pipeline in 3Q15
03:28PM  Dividend Aristocrats Part 47: AbbVie Inc (ABBV) at Insider Monkey
03:06PM  Abbott Laboratories 4Q15 EPS Expected to Rise Significantly
02:55PM  Halozyme Gets $5M as AbbVie Begins Dosing in Humira Trial
08:35AM  4 Jefferies Growth Stocks to Buy as January Selling Presents Big Opportunity at 24/7 Wall St.
08:07AM  Revlimid Continues to Drive Celgenes Revenue
08:02AM  AbbVie, Inc. breached its 50 day moving average in a Bullish Manner : January 22, 2016
Jan-21-16 02:54PM  Halozyme Confirms $5 Million Milestone Payment From AbbVie
08:30AM  MD Anderson, AbbVie Connect to Advance Cancer Immunotherapy PR Newswire
08:05AM  AbbVie Trades at Discounted Valuations Compared to Its Peers
Jan-20-16 05:00PM  3 Healthcare Stocks That Actually Gained Ground Last Week at Motley Fool
03:15PM  Galapagos (GLPG) Gives Update on Cystic Fibrosis Program
11:06AM  AbbVie Expects Imbruvica Revenues to Reach $5 Billion in 2020
09:37AM  [$$] AbbVie Leukemia Therapy Granted FDA Breakthrough Designation at The Wall Street Journal
08:30AM  AbbVie's Venetoclax Receives Breakthrough Therapy Designation from FDA in Combination with Rituximab for the Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia PR Newswire
Jan-19-16 02:00PM  Is AbbVie a Good Stock To Buy? at Investopedia
01:06PM  Intellectual Property Should Safeguard Humiras Top Spot
12:29PM  3 Slides That Perfectly Sum Up Where AbbVie Is Headed Next at Motley Fool
10:07AM  AbbVies Late-Stage Research Pipeline Could Boost Future Revenues
08:06AM  AbbVie Is Expected to Strengthen Its Position in Virology in 4Q15
06:24AM  Avoid the Market Carnage With These 5 Big Stocks at TheStreet
01:32AM  Galapagos advances CF clinical development GlobeNewswire
Jan-18-16 08:30AM  AbbVie (ABBV) Looks Good: Stock Adds 5.1% in Session
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company's products include HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; VIEKIRA PAK, an all-oral, short-course, interferon-free therapy, with or without ribavirin, for adult patients with genotype 1 chronic hepatitis, including those with compensated cirrhosis; Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in people with HIV-1; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1 infection; and Synagis to prevent respiratory syncytial virus infection in high risk infants. It also provides AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, and the treatment of endometriosis and central precocious puberty, as well as for the preoperative treatment of patients with anemia. In addition, the company offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; TriCor, Trilipix, Niaspan, Simcor, and Advicor to treat metabolic conditions characterized by high cholesterol and/or high triglycerides; and Zemplar to treat secondary hyperparathyroidism. It sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. The company has strategic collaboration with Calico Life Sciences LLC, Infinity Pharmaceuticals, Inc., Ablynx NV, Galapagos NV, Alvine Pharmaceuticals, Inc., and Action Pharma A/S. AbbVie Inc. was incorporated in 2012 and is based in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GONZALEZ RICHARD AChairman of the Board and CEOJul 29Option Exercise35.8865,0002,332,200538,187Jul 31 05:41 PM
GONZALEZ RICHARD AChairman of the Board and CEOJul 29Sale71.0924,9791,775,656513,208Jul 31 05:41 PM
GONZALEZ RICHARD AChairman of the Board and CEOJul 29Sale71.2440,0212,851,264473,187Jul 31 05:41 PM
HURWICH THOMAS A.VP, ControllerMay 19Option Exercise22.946,200142,23274,660May 21 05:50 PM
HURWICH THOMAS A.VP, ControllerMay 19Sale66.006,200409,20068,460May 21 05:50 PM
GONZALEZ RICHARD AChairman of the Board and CEOApr 28Option Exercise35.88175,4776,296,115657,624Apr 30 06:01 PM
GONZALEZ RICHARD AChairman of the Board and CEOApr 28Sale64.6795,9706,206,473554,660Apr 30 06:01 PM
GONZALEZ RICHARD AChairman of the Board and CEOApr 28Sale64.928,281537,569482,147Apr 30 06:02 PM
GONZALEZ RICHARD AChairman of the Board and CEOApr 08Sale64.726,994452,652561,360Apr 30 06:01 PM
Schumacher Laura JEVP, Bus.Dev.,Ext.Aff.&GCMar 02Sale60.3025,0001,507,500274,116Mar 03 06:10 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesMar 02Sale60.3012,314742,534106,954Mar 03 06:07 PM
SALEKI-GERHARDT AZITASVP, OperationsFeb 27Sale60.472,112127,706104,555Mar 03 06:09 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesFeb 27Sale60.512,074125,492123,860Mar 03 06:07 PM
HURWICH THOMAS A.VP, ControllerFeb 27Sale60.571,18571,77770,322Mar 03 06:06 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesFeb 17Sale58.7024114,147106,592Feb 19 05:51 PM